This NDC is on FDA's drug shortage list (posted Mar 13, 2023)
Reported reason: Demand increase for the drug
Product Information
METHOTREXATE 50 MG/2 ML VIAL is a generic product labeled by Hikma Pharmaceuticals USA Inc., priced at $1.2370 per ML under NDC 00143951910. Its NADAC has been published 226 times since Apr 11, 2018.
FDA first approved this application on Sep 16, 1986. Its Orange Book therapeutic-equivalence code is AP.
Strength
25 mg/mL
Manufacturer
Hikma Pharmaceuticals USA Inc.NDC
00143951910
Classification
Generic
Dosage Form
SOLUTION
Route
INTRA-ARTERIAL; INTRAMUSCULAR; INTRATHECAL; INTRAVENOUS
Effective Date
9/23/2026
Active Ingredients
METHOTREXATEApproval Type
Generic (ANDA)
FDA Application
ANDA089340FDA Approved
9/16/1986
TE Code
AP
On Market Since
10/10/2017
Pharmacological Classes
Price Statistics
The NADAC for METHOTREXATE 50 MG/2 ML VIAL has been published 226 times since Apr 11, 2018, and over the history we have for it it has declined 28.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.2370 per ML |
|---|---|
| All-time high | $1.7314 (Jul 11, 2018) |
| All-time low | $1.1511 (Jan 17, 2024) |
| 52-week high | $1.3431 |
| 52-week low | $1.2060 |
| Median price | $1.3518 |
| Average price | $1.3636 |
| Largest weekly change | +14.9% (Feb 21, 2024) |
| Weeks tracked | 226 |
| Tracking since | Apr 11, 2018 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Methotrexate market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Hikma Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methotrexate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Folate Analog Metabolic Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHOTREXATE 50 MG/2 ML VIAL?
The current National Average Drug Acquisition Cost (NADAC) for METHOTREXATE 50 MG/2 ML VIAL, manufactured by Hikma Pharmaceuticals USA Inc., is $1.2370 per ML (NDC 00143951910), effective Sep 30, 2026.
How has the price of METHOTREXATE 50 MG/2 ML VIAL changed over time?
Over the history we have for it, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has declined 28.0%. It has been tracked across 226 weekly CMS publications since Apr 11, 2018.
What are the highest and lowest recorded NADAC prices for METHOTREXATE 50 MG/2 ML VIAL?
Since Apr 11, 2018, the NADAC for METHOTREXATE 50 MG/2 ML VIAL has ranged from a low of $1.1511 (Jan 17, 2024) to a high of $1.7314 (Jul 11, 2018), with a median of $1.3518 per ML.
Are there cheaper alternatives to METHOTREXATE 50 MG/2 ML VIAL?
No other NADAC-published product currently shares the active ingredient and strength of METHOTREXATE 50 MG/2 ML VIAL in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures METHOTREXATE 50 MG/2 ML VIAL?
METHOTREXATE 50 MG/2 ML VIAL (NDC 00143951910) is labeled by Hikma Pharmaceuticals USA Inc., and CMS classifies it as a generic product.
Is METHOTREXATE 50 MG/2 ML VIAL in shortage?
Yes — NDC 00143951910 is currently listed in FDA's drug shortage database (posted Mar 13, 2023). Reported reason: Demand increase for the drug.